

CURRICULUM VITAE

Kenneth J. Kopeccky, Ph.D.

Current Address: Southwest Oncology Group
 Fred Hutchinson Cancer Research Center
 1100 Fairview Avenue North, M3-C102
 PO Box 19024
 Seattle, WA 98109-1024

Phone: (206) 667-4623

Email: kkopecky@fhcrc.org

Education: University of California-Los Angeles, BA, (Mathematics), 1971
 Oregon State University, MS, (Statistics), 1975
 Oregon State University, PhD, (Statistics), 1977

Positions:

Graduate Research Assistant, Department of Mathematics, California State College, Bakersfield, California, 1972-1973.

Graduate Research Assistant, Department of Statistics, Oregon State University, Corvallis, Oregon, 1973-1977.

Senior Fellow, Department of Biostatistics, University of Washington, Seattle, Washington, 1977-1978.

Postdoctoral Trainee, Program in Epidemiology & Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1977-1978.

Associate, Program in Epidemiology & Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1978-1980.

Affiliate Assistant Professor, Department of Biostatistics, University of Washington, Seattle, Washington, 1978-1980.

Research Assistant Professor, Department of Biostatistics, University of Washington, Seattle, Washington, 1980-1985.

Assistant Member, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1980-1985.

Research Associate, Radiation Effects Research Foundation, Hiroshima, Japan, 1982-1985.

Associate Member, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1985-1991.

Research Associate Professor, Department of Biostatistics, University of Washington, Seattle, Washington, 1985-1993 .

Member, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1991-present.

Affiliate Associate Professor, Department of Biostatistics, University of Washington, Seattle, Washington, 1993-1994.

Affiliate Professor, Department of Biostatistics, University of Washington, Seattle, Washington, 1994-present.

Consultant, Department of Statistics, Radiation Effects Research Foundation, Hiroshima, Japan, 2005-present.

Honors:

National Merit Scholar, 1967
Phi Beta Kappa
Pi Mu Epsilon
Omega Rho
Jerome C. R. Li Award, 1977

Societies:

American Statistical Association
International Biometric Society
Society for Clinical Trials

Committees:

Director, Data Coordinating Center for study, "Predictive Value of Wolfe Class in BCDDP Women". Fred Hutchinson Cancer Research Center, Seattle, Washington, 1979-1982.
Short Course Chairman, Statistics and Epidemiology Research Corporation, Seattle, Washington, 1980-1982.
Member, Scientific Reports Review Committee, Radiation Effects Research Foundation, 1983-1985.
Member, Research Protocol Review Committee, Radiation Effects Research Foundation, 1985.
Biostatistician, Southwest Oncology Group Leukemia Committee, 1986-present.
Member, Technical Steering Panel, Hanford Environmental Dose Reconstruction Project, 1988-1995.
Vice-Chair and biostatistician, Southwest Oncology Group Leukemia Biology Program, 1988-present.
Member, Institutional Review Board, Fred Hutchinson Cancer Research Center, 1988-1990.
Member, Space and Resources Committee, Fred Hutchinson Cancer Research Center, 1989-1993.
Member, Organizing Committee, ASA 1992 Conference on Radiation and Health, 1992.
Member, NCRP Scientific Committee 64-19 (Historical Dose Evaluation) 1994-2003.
Biostatistician, Southwest Oncology Group Bone Marrow and Stem Cell Transplantation Committee, 1996-present.
Member, International Biometric Society Council, 1996-1999.
Member, Gulf War Veterans' Illness 1997 Proposal Review Committee, 1997.
Member, Committee on Risk Assessment of Exposure to Radon in Drinking Water, National Research Council, 1997-2000.
Member, ad hoc Review Panel, Epidemiologic Studies of Cancer Among Atomic Bomb Survivors, 1997.
Member, NCI Special Emphasis Review Panel, 1997.
Member, Committee on Dosimetry for the Radiation Effects Research Foundation, National Research Council, 1998-2002.
Member, Awards Fund Committee, International Biometric Society, 1998-present.
Chair, Data Analysis Working Group, International Consortium for Research on the Health Effects of Radiation, 1999-2004.
Member, Institutional Review Board, Cancer Research and Biostatistics, 1999-2001.
Chair, NCI Common Data Elements Committee - Leukemia, 2000-2003.
Member, FHCRC Clinical Division DSMB (Multi-Institution Nonmyeloablative Transplant Studies), 2001-present.
Member, NCI Common Data Elements Committee - Leukemia Pathology, 2001-2003.
Member, NCI Common Data Elements Committee - Lymphoma, 2002-2003.
Member, NCI Common Data Elements Committee - Pediatric Leukemia, 2001-2003.
Member, International Working Group to Standardize Response Criteria in AML, 2001.
Member, Expert Group "Health", WHO/Chernobyl Forum, 2003-2004.
Member, International Thyroid Working Group, 2003-2004.
Member, Subcommittee on Acute Leukemia in the Elderly, ASH/FDA Workshop on Endpoints in Hematologic Malignancies, 2005.

Member, Radiation Effects Research Foundation Recruitment Committee, National Research Council, 2005-present.

Member, NCRP Scientific Committee 6-4 (Fundamental Principles of Dose Reconstruction), 2006-present.

Member, Group Banking Committee Steering Committee, 2006-present.

Member, NCI Leukemia Steering Committee, 2010-present.

Other Professional Activities:

Treasurer, Western North American Region, International Biometric Society, 2004-2008.

Teaching:

University of Washington

Courses:

Biostatistics 472A, Winter, 1982

Biostatistics 590A, Spring, 1987

Biostatistics 580A, Winter, 1992

Master's and Ph.D. Student Committees:

William E. Barlow, Ph.D., 1986, Biostatistics

Michael P. Jones, Ph.D., 1986, Biostatistics

Diana Farrow, Ph.D., 1989, Epidemiology

Marcia A. Ciol, Ph.D., 1991, Biostatistics

Gary Longton, M.S., 1987, Biostatistics

James G. Gurney, Ph.D., 1994, Epidemiology

Chris Bynum, Ph.D., 1994, Epidemiology

Casey Crump, Ph.D., 1998, Epidemiology

Eric Grant, Ph.D., 2007, Epidemiology

Jean McDougall, M.S., 2008, Epidemiology

Jean McDougall, Ph.D., 2010, Epidemiology

PRESENTATIONS:

1. Kopecky KJ. Statistical methods for cell survival data from in vitro radiosensitivity assays. Japan Radiation Research Society, Kyoto, 1983.
2. Kopecky KJ, Preston DL. Improved Monte Carlo estimation of statistical significance for tests of trend in rates or proportions. International Biometric Conference, Tokyo, 1984.
3. Kopecky KJ. Japanese Lifespan Study: Atomic bomb survivors-radiation and risk of lung cancer. Epidemiology of Radon and Lung Cancer, Pittsburgh, 1986.
4. Kopecky KJ. Analysis of treatment outcomes by delivered dose-problems and pitfalls. American Public Health Association, Las Vegas, 1986.
5. Kopecky KJ. Reassessment of A-bomb dosimetry: dose estimation methods and preliminary cancer mortality findings. The Biometric Society, Dallas, 1987.
6. Kopecky KJ. Health effects of ionizing radiation among Japanese atomic bomb survivors. Society for Epidemiologic Research, Amherst, 1987.
7. Kopecky KJ. The Hanford Thyroid Disease Study. Statistical strategies in environmental modeling and monitoring, National Institute of Statistical Sciences. Durham NC, 1991.
8. Kopecky KJ. The Hanford Thyroid Disease Study. ASA 1992 Conference on Radiation and Health, 1992.

9. Kopecky KJ. Studies of the effects of radioactive materials released from the Hanford site. International Conference on Environmental Problems: Issues, Statistical Models, and Methods. Calcutta, 1993.
10. Kopecky KJ. Radiation risk estimation: challenges and realities in conducting epidemiological studies. Radiation Health Effects: Biology, Risk Estimation, and Protection. Hiroshima, Japan, 2004.
11. Kopecky KJ. Risk of thyroid cancer in relation to estimated radiation dose from the Chernobyl accident: a population-based case-control study in Bryansk Oblast, Russian Federation. AACR Conference on Frontiers in Cancer Prevention Research, Seattle, 2004.
12. Kopecky, KJ. Thyroid cancer in the Bryansk region of the Russian Federation following the Chernobyl accident: results of an international collaboration. European Thyroid Association – Cancer Research Network. Naples, 2006.
13. Kopecky, KJ. Health consequences of the Chernobyl accident. International Symposium to Commemorate the 15th Anniversary of HICARE. Hiroshima, Japan, 2006.
14. Kopecky K, Williams LA. Modeling effects of radiation exposure on disease outcomes with radiation-influenced risk factors (RFs), using Adult Health Study (AHS) data. JSM, 2007.

BIBLIOGRAPHY

1. Kopecky KJ, Pierce DA. Efficiency of smooth goodness-of-fit tests. *JASA* 74:393-397, 1979.
2. Pierce DA, Kopecky KJ. Testing goodness-of-fit for the distribution of errors in regression models. *Biometrika* 66:1-5, 1979.
3. Pierce DA, Stewart WH, Kopecky KJ. Distribution free regression analysis of grouped survival data. *Biometrics* 35:785-793, 1979.
4. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rapoport JM, Santo SG, Gordon-Smith EC, Storb R. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. *Blood* 53(3):504-514, 1979.
5. Singer JW, Fialkow PJ, Adamson JW, Steinmann L, Ernest C, Murphy S, Kopecky KJ. Polycythemia Vera: Increased expression of normal committed granulocytic stem cells in vitro after exposure of marrow to tritiated thymidine. *J Clin Invest* 64:1320-1324, 1979.
6. Tsoi M-S, Storb R, Dobbs S, Kopecky KJ, Santos E, Weiden PL, Thomas ED. Nonspecific suppressor cells in patients with chronic graft-vs-host disease after marrow grafting. *J Immun* 123(5):1970-1976, 1979.
7. Johnstone M, Tanner D, Chau B, Kopecky KJ. Concentration-dependent morphologic effects of cytochalasin B in the aqueous outflow system. *Invest Ophthalmology and Visual Science* 19:835-841, 1980.
8. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED. An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation. *Gastroenterology* 79(6):1178-1191, 1980.
9. Atkinson K, Storb R, Weiden PL, Deeg HJ, Kopecky KJ, et al. Studies on transplantation tolerance in canine radiation chimeras. *Biology of Bone Marrow Transplantation. ICN-UCLA Symposia on Molecular and Cellular Biology, Vol XVII (Gale RF and Fox CF, eds.)*. Academic Press, New York, pp. 271-280, 1980.

10. Witherspoon R, Storb R, Ochs HD, Flournoy N, Kopecky KJ, Sullivan KM, Deeg JH, Sosa R, Noel DR, Atkinson K, Thomas ED. Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time post-transplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. *Blood* 58(2):360-368, 1981.
11. Sale GE, Shulman HM, Schubert MM, Sullivan KM, Kopecky KJ, et al. Oral and ophthalmic pathology of graft-versus-host disease in man; predictive value of the lip biopsy. *Hum Pathol* 12:1022-1030, 1981.
12. Tsoi M-S, Storb R, Weiden P, Santos E, Kopecky KJ, Thomas ED. Sequential studies of lymphocyte responses to host fibroblasts in 51 patients given HLA-identical marrow grafts. *J Immunol* 128:239-242, 1981.
13. Springmeyer S, Altman LC, Kopecky K, Storb R. Alveolar macrophage kinetics and function after interruption of canine marrow function. *Am Rev Res Dis* 125:347-351, 1981.
14. Witherspoon RP, Kopecky KJ, Storb RF, et al. Immunologic recovery in 48 patients following syngeneic marrow transplantation for hematologic malignancy. *Transplantation* 33:143-149, 1981.
15. Carlile T, Thompson DJ, Kopecky KJ, et al. Reproducibility and consistency in classification of breast parenchymal patterns. *Am J Roentgenol* 140:1-7, 1983.
16. Schmidt E, Deeg HJ, Lum LG, Kopecky KJ, Storb R. Identification of immunoglobulin-secreting cells among canine peripheral blood mononuclear cells by the protein A hemolytic plaque assay. *Exp Hematol* 11:193-201, 1983.
17. Steinhorn SC, Kopecky KJ, Myers MH, Ball C. Characteristics of colon cancer patients reported in population-based tumor registries and comprehensive cancer centers. *J Natl Cancer Inst* 70:629-634, 1983.
18. Springmeyer SC, Kopecky KJ, Deeg HJ, et al. Pulmonary bronchoalveolar cell and protein kinetics in dogs given total-body irradiation, autologous marrow grafts, and methotrexate. *Transplantation* 37:336-339, 1984.
19. Kopecky KJ. Utilization of the Adult Health Study Data: Resources and methods of past and current analyses. IN *Atomic Bomb Survivor Data: Utilization and Analysis* (Prentice RL and Thomson DJ, eds.). SIAM, Philadelphia, pp. 197-218, 1984.
20. Miller RC, Hiraoka T, Nakamura N, Tenou H, Kopecky KJ, Jones MP, Gould MN. In vitro culture techniques for human thyroid cells: Methods and application to radiation biology. (RERF Tech. Report 10-84) *J Radiat Res* 26:269-282, 1985.
21. Hiraoka T, Miller RC, Gould MN, Kopecky KJ, Ezaki H, Takeichi N, Ito T, Clifton KH. Survival of human normal thyroid cells after X-ray irradiation. (RERF Tech. Report 13-84) *Int J Radiat Biol* 47:299-307, 1985.
22. Preston DL, Kopecky KJ, Kato H. Analyses of mortality and disease incidence among atomic bomb survivors. IN *Proceedings of the US-Japan Conference on Statistical Methods in Cancer Epidemiology* (WJ Blot, T Hirayama, DG Hoel, eds.). Radiation Effects Research Foundation, Hiroshima, 1985.
23. Whitehead JR, Carlile T, Kopecky KJ, et al. Wolfe mammographic parenchymal patterns: A study of the masking hypothesis of Egan and Mosteller. *Cancer* 56:1280-1286, 1985.

24. Whitehead JR, Carlile T, Kopecky KJ, et al. The relationship between Wolfe's classification of mammograms, accepted breast cancer risk factors, and the incidence of breast cancer. *Am J Epidemiol* 122:994-1006, 1985.
25. Carlile T, Kopecky KJ, Thompson DJ, et al. Breast cancer prediction and the Wolfe classification of mammograms. *JAMA* 254:1050-1053, 1985.
26. Radford EP, Preston DL, Kopecky KJ. Methods for study of delayed health effects of A-bomb radiation. *Gann Monograph on Cancer Research* No. 32, 1986.
27. Miller RC, Kopecky KJ, Hiraoka T, Ezaki H, Clifton KH. Comparison of radiosensitivities of human autologous normal and neoplastic thyroid epithelial cells. *Br J Radiol* 59:127-130, 1986.
28. Preston DL, Kato H, Kopecky KJ, Fujita S. Life Span Study report 10, Part 1, Cancer mortality among A-bomb survivors in Hiroshima and Nagasaki, 1950-82. *RERF Tech. Report* 1-86, 1986.
29. Kopecky KJ, Preston DL. The impact of the reassessment of A-bomb dosimetry: Dose estimation methods and preliminary cancer mortality findings. *RERF Tech. Report* 11-86, 1986.
30. Kopecky KJ, Nakashima E, Yamamoto T, Kato H. Lung cancer, radiation and smoking among A-bomb survivors, Hiroshima and Nagasaki. *RERF Tech. Report* 13-86, 1986.
31. Kopecky KJ, Preston DL. Improved Monte Carlo estimation of statistical significance for tests of trends in rates or proportions. (*RERF Tech. Report* 6-85) *J Statist Comp Simul* 27:339-361, 1987.
32. Yamamoto T, Kopecky KJ, Fujikura T, et al. Lung cancer incidence among Japanese A-bomb survivors, 1950-80. *RERF TR* 12-86. *J Radiat Res* 28:156-171, 1987.
33. Miller RC, Hiraoka T, Kopecky KJ, et al. Sensitivity to radiation of human normal, hyperthyroid, and neoplastic thyroid epithelial cells in primary culture. (*RERF Tech. Report* 2-86) *Radiat Res* 111:81-91, 1987.
34. Kopecky KJ. Contribution to discussion of "Modelling the relative and absolute risks of radiation-induced cancers" by CR Muirhead and SC Darby. *J R Stat Soc (A)*, 150:109, 1987.
35. Ryan DH, Kopecky KJ, Bickers JN, et al. Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: A Southwest Oncology Group study. *Cancer Treat Rep* 71(7-8):713-716, 1987.
36. Kopecky KJ. Prediction of cancer mortality induced by exposure to low levels of ionizing radiation. *Northwest Environmental Journal* 3:23-37, 1987.
37. Preston DL, Kato H, Kopecky KJ, Fujita S. Studies of the mortality of A-bomb survivors. *Cancer Mortality, 1950-82*. *Radiat Res* 111:151-178, 1987.
38. Clift RA, Buckner CD, Thomas ED, Kopecky KJ, et al. The treatment of acute non-lymphoblastic leukemia by allogeneic bone marrow transplantation. *Bone Marrow Transplant* 2:243-258, 1987.
39. Goodwin JW, Kopecky KJ, Slavik M, et al. Phase II evaluation of spirogermanium in malignant melanoma: A Southwest Oncology Group study. *Cancer Treat Rep* 71(10):985-986, 1987.
40. Doney K, Buckner CD, Kopecky KJ, et al. Marrow transplantation for patients with acute lymphoblastic leukemia in first marrow remission. *Bone Marrow Transplant* 2:355-363, 1988.

41. Bowden RA, Dobbs S, Kopecky KJ, et al. Increased cytotoxicity against cytomegalovirus-infected target cells by bronchoalveolar lavage cells from marrow transplant patients with cytomegalovirus pneumonia. *J Infect Dis* 158(4):773-779, 1988.
42. Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia: *Nouv Rev Fr Hematol* 30:457-450, 1988.
43. Tallman MS, Kopecky KJ, Amos D, et al. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. *J Clin Oncol* 7(3):326-337, 1989.
44. Head DR, Kopecky K, Bennett JM, et al. Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. *Cancer* 64:2199-2202, 1989.
45. Voltarelli JC, Przepiorka D, Shankar P, Kopecky K, Martin PJ, Torok-Storb B. CD8+/DR+/CD25- T-lymphocytes associated with marrow graft failure. *Bone Marrow Transplantation* 4:647-652, 1989.
46. Doney K, Kopecky K, Storb R, et al. Long-term comparison of immunosuppressive therapy with antithymocyte globulin to bone marrow transplantation in aplastic anemia. IN: *Aplastic Anemia and Other Bone Marrow Failure Syndromes*, NT Shahidi (ed), Springer-Verlag Chap 9, 1990.
47. Reed EC, Wolford JL, Kopecky KJ, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. *Ann Intern Med* 112(7):505-510, 1990.
48. Mortimer JE, Schulman S, MacDonald JS, Kopecky K, Goodman G. High-dose cisplatin in disseminated melanoma: A comparison of two schedules. *Cancer Chemother Pharmacol* 25:373-376, 1990.
49. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin: A controlled clinical trial in bone marrow transplantation. *N Engl J Med* 323(11):705-712, 1990.
50. Radich JP, Kopecky KJ, Willman CL, et al. N-ras Mutations in adult de novo acute myelogenous leukemia: incidence and clinical significance. *Blood* 76(4):801-807, 1990.
51. Kish JA, Kopecky KJ, Samson MK, et al. Evaluation of fludarabine phosphatase in malignant melanoma: A Southwest Oncology Group study. *Invest New Drugs* 9:105-108, 1991.
52. Self SG, Longton G, Kopecky KJ, Liang K-Y. Estimating HLA/disease association with application to a study of aplastic anemia. *Biometrics* 47:53-61, 1991.
53. Sullivan KM, Kopecky KJ, Buckner CD, Storb R. Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation. *N Engl J Med* 324:631-633, 1991.
54. Whitehead RP, Kopecky KJ, Samson MK, et al. Phase II study of IV bolus recombinant interleukin 2 in advanced malignant melanoma: A Southwest Oncology Group study. *J Natl Cancer Inst* 83(17):1250-1252, 1991.
55. Ryan DH, Kopecky KJ, Head D, et al. Analysis of treatment failure in acute non-lymphocytic leukemia patients over 50 years of age. *Am J Clin Oncol* 15(1):69-75, 1992.
56. Radich JP, Kopecky KJ, Appelbaum F, Willman CL, Collins SJ. N-ras mutations in acute myelogenous leukemia: A review of the current literature and an update of the Southwest Oncology Group experience. *Leuk Lymphoma* 6:325-334, 1992.

57. Morrison FS, Kopecky KJ, Head DR, et al. Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia -results of a Southwest Oncology Group study Rubidazone vs. Adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and Levamisole maintenance. *Leukemia* 6:708, 1992.
58. Bowden RA, Mori M, Dobbs S, Hackman R, Kopecky KJ, Crawford S. Mononuclear cell reconstitution in the lung after marrow transplant: Lack of influence of CMV pneumonia, irradiation and graft-versus-host disease. *Transplantation* 55:557-561, 1993.
59. Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who are not in first remission: A Southwest Oncology Group study. *Blood* 81(8):2187-2193, 1993.
60. Slavik M, Kopecky KJ, Sondak VK, et al. Evaluation of Amonofide in disseminated melanoma: A Southwest Oncology Group study. *Invest New Drugs* 11:223-226, 1993.
61. Sondak VK, Kopecky KJ, Liu PY, et al. Didemnin B in metastatic malignant melanoma: A phase II trial of the Southwest Oncology Group. *Anticancer Drugs* 5:147-150, 1994.
62. Scott AA, Head DR, Kopecky KJ, et al. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. *Blood* 84(1):244-255, 1994.
63. Kuss BJ, Deeley RG, Cole SPC, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Lane SA, Nancarrow JK, Whitmore SA, Callen DF. Deletion of the gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. *Lancet* 343:1531-1534, 1994.
64. Radich JP, Kopecky KJ, Boldt DH, et al. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. *Leukemia* 8(10):1688-1695, 1994.
65. Boldt DH, Kopecky KJ, Head D, et al. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology experience. *Leukemia* 8(12):2118-2126, 1994.
66. Head DR, Kopecky KJ, Willman C, Appelbaum FR. Treatment outcome with chemotherapy in acute promyelocytic leukemia: The Southwest Oncology Group experience. *Leukemia* 8(2):S38-S41, 1994.
67. Head DR, Kopecky KJ, Willman C, Appelbaum FR. Reply to comments by Fenaux and Warrell. *Leukemia* 8(2):S62, 1994.
68. Siadak MF, Kopecky KJ, Sullivan K. Reduction in transplant-related complications in patients given intravenous immunoglobulin after allogeneic marrow transplantation. *Clin Exp Immunol* 97(S1):53-57, 1994.
69. Grever M, Kopecky KJ, Foucar MK, et al. Randomized comparison of pentostatin vs interferon alpha-2a in previously untreated patients with hairy cell leukemia: An intergroup study. *J Clin Oncol* 13(4):974-982, 1995.
70. Bigelow CL, Kopecky KJ, Files JC, et al. Treatment of acute myelogenous leukemia in patients over fifty years of age with V-TAD: A Southwest Oncology Group study. *Amer J Hematol* 48:228-232, 1995.

71. Kopecky KJ, Davis S, Hamilton T, Amundson B. Clarification of Hanford Thyroid Disease study. *Health Physics Society Newsletter* 23(7):24-25, 1995.
72. Slovak ML, Kopecky KJ, Wolman SR, et al. Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: A Southwest Oncology Group study (SWOG 8612). *Leuk Res* 19(6):381-388, 1995.
73. Slovak ML, Traweek ST, Willman CL, Head DR, Kopecky KJ, Magenis RE, Appelbaum FR, Forman SJ. Trisomy 11: an association with stem/progenitor cell immunophenotype. *Br J Hematol* 90:266-273, 1995.
74. Hewlett J, Kopecky KJ, Head D, et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): A Southwest Oncology Group study. *Leukemia* 9(4):562-569, 1995.
75. Head DR, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. *Blood* 86(5):1717-1728, 1995.
76. Leith C, Chen I-M, Kopecky KJ, et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR1-/efflux+ and MDR1+/efflux- cases. *Blood* 86(6):2329-2342, 1995.
77. Welborn JL, Kopecky KJ, Meyers FJ, et al. Carboplatin infusion in relapsed and refractory acute myeloid leukemia-Southwest Oncology Group trial. *Leukemia* 9:1126-1129, 1995.
78. Meyskens F, Kopecky KJ, Taylor CW, et al. A randomized trial of adjuvant human interferon- γ versus observation in high risk malignant melanoma: A Southwest Oncology Group study. *J Natl Cancer Inst* 87(22):1710-1711, 1995.
79. Meyskens FL, Kopecky KJ, Appelbaum FR, et al. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: A Southwest Oncology Group trial. *Leuk Res* 19(9):605-612, 1995.
80. Grever M, Kopecky K, Appelbaum F, Foucar MK. Reply to letter of Toussard and Flandrin. *J Clin Oncol* 13(10):2678-2679, 1995.
81. Gurney JG, Mueller BA, Davis S, Schwartz SM, Stevens RG, Kopecky KJ. Childhood brain tumor occurrence in relation to residential power line configurations, electrical heating sources, and electrical appliance use. *Am J Epidemiol* 143(2):120-128, 1996.
82. Sullivan KM, Storek J, Kopecky KJ, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. *Bone Marrow Transplant* 2:44-53, 1996.
83. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia. *Blood* 88(8):2841-2851, 1996.
84. Slovak ML, Kopecky KJ, McConnell T, et al. A subgroup of elderly AML patients with a high complete remission rate can be defined. *Trends in Onco-Hematology* 4(2):34-35, 1996.

85. Kuss JB, Deeley RG, Cole SPC, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Callen DF. The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. *Leuk Lymphoma* 20:357-364, 1996.
86. Sondak VK, Kopecky KJ, Meyskens FL. Reply to letter of Lollini, et al. *J Natl Cancer Inst* 88(13):927, 1996.
87. Davis S, Kopecky KJ, Hamilton T, Amundson B. The Hanford Thyroid Disease Study. IN *Environmental Dose Reconstruction and Risk Implications: Proceedings of the Thirty-First Annual Meeting of the National Council on Radiation Protection and Measurements*. JE Till, editor. NCRP, Bethesda, MD. 1996.
88. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. *Blood* 89(9):3323-3329, 1997.
89. Leith, CP, Kopecky KJ, Chen, I-M, Appelbaum FR, Head DR, Godwin JE, Willman CL. "Development of a highly sensitive multiparameter flow cytometric assay correlating MDR1 expression and function: Clinical application to acute myeloid leukemia." In: Pieters R, Kaspers GJL and Veerman AJP, editors. *Drug Resistance in Leukemia and Lymphoma II (Advances in Blood Disorders, series 3, chapter 37)*. Amsterdam: Harwood Academic Publishers; p. 307-314, 1997.
90. Sondak VK, Kopecky KJ, Smith JW II, et al. "Is interferon- γ detrimental? Results of a Southwest Oncology Group randomized trial of adjuvant human interferon- γ versus observation in malignant melanoma." In: Salmon SE, editor. *Adjuvant Therapy of Cancer VIII*. Philadelphia, Pennsylvania: Lippincott-Raven; p. 259-272, 1997.
91. Appelbaum FR, Kopecky KJ. Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group. *Cancer* 80:2199-2204, 1997.
92. Godwin J, Kopecky KJ, Head DR, et al. A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia. A Southwest Oncology Group study (9031). *Blood* 91(10):3607-3615, 1998.
93. Leith CP, Kopecky KJ, Chen I-M, et al. AML in the elderly: a biologically distinct disease in which MDR1 expression and unfavorable cytogenetics contribute to poor clinical response. *Studies of the Southwest Oncology Group*. In: Hiddeman W; Buchner T; Wormann B, et al., editors. *Acute Leukemias VII: Experimental Approaches and Novel Therapies*. Berlin, Heidenberg: Springer-Verlag; 1998. p 413-421.
94. Hogge DE, Willman CL, Kreitman RJ, Berger M, Hall PD, Kopecky KJ, McLain C, Tagge EP, Eaves CJ, Frankel AE. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony stimulating factor fusion protein. *Blood* 92(2):589-595, 1998.
95. Appelbaum FR, Kopecky KJ, Willman CL. Response: sensitive and specific assessment of MDR1 is essential to determine prognostic impact in AML. Reply to letter from Stasi, et al. *Blood* 92(2):696-697, 1998.
96. Leith CP, Kopecky KJ, Willman CL. Response: biologic features of acute myeloid leukemia in the elderly. Reply to letter from Venditti, et al. *Blood* 92(2):698-699, 1998.

97. Li Q, Kopecky KJ, Mohen A, Willman C, Appelbaum FR, Weick JK, Issa J-P. Estrogen receptor methylation is associated with improved survival in adult myeloid leukemia. *Clinical Cancer Research* 5:1077-1084, 1999.
98. Committee on Risk Assessment of Radon in Drinking Water (Doull J, Borak TB, Cleaver JE, Eckerman KF, Gundersen LCS, Harley NH, Hess CT, Hopke PK, Kinner NE, Kopecky KJ, McKone TE, Sextro RG). Risk Assessment on Radon in Drinking Water. National Academy Press, Washington DC, 1999.
99. Leith CP, Kopecky KJ, Chen I-M, Eijdem L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. *Blood* 94(3):1086-1099, 1999.
100. Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, Vial RH, Lichtin A, Nand S, Samlowski WE, Appelbaum FR. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia: A Southwest Oncology Study. *Leukemia Research* 23(9):787-94, 1999.
101. Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine with 2'-deoxycoformycin and prediction of early relapse. *Clinical Cancer Research* 5(7):1665-1670, 1999.
102. Kopecky KJ. Comments on the Hanford Thyroid Disease Study. In Proceedings of the Workshop "Uncertainties in Radiation Dosimetry and Their Impact on Dose-Response Analyses," Bethesda, Maryland, September 3-5, 1997 (E Ron and FO Hoffman, eds.) NIH Publication No. 99-4541. National Institutes of Health, Bethesda, 1999.
103. Hopke PK, Borak TB, Doull J, Cleaver JE, Eckerman KF, Gundersen LCS, Harley NH, Hess CT, Kinnear NE, Kopecky KJ, McKone TE, Sextro RG, Simon S. The health risks due to radon in drinking water. *Environmental Science and Technology* 34(6):921-926, 2000.
104. Zhang H, Murata-Collins JL, Gaytan P, Forman SJ, Kopecky KJ, Williman CL, Appelbaum FR, Slovak ML. Twenty-four-color special karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. *Genes, Chromosomes & Cancer* 28:318-320, 2000.
105. Rimsza LM, Kopecky KJ, Ruschulte J, Chen IM, Slovak ML, Karanes C, Godwin J, List A, Williman CL. Microsatellite instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature. *Leukemia* 14:1044-1051, 2000.
106. Chauncey TR, Rankin C, Anderson JE, Chen IM, Kopecky KJ, Godwin JE, Kalaycio ME, Moore DF Jr, Shurafa M, Petersdorf SH, Kraut EH, Leith CP, Head DR, Luthardt FW, Willman CL, Appelbaum FR. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group study 9617. *Leukemia Research* 24:567-574, 2000.
107. Crump C, Chen C, Appelbaum FR, Kopecky KJ, Schwartz SM, Weiss NS. Glutathione S-transferase theta 1 gene deletion and risk of acute myelocytic leukemia. *Cancer Epidemiology, Biomarkers, and Prevention* 9(5):457-460, 2000.
108. Flinn I, Kopecky KJ, Foucar K, Head D, Bennett J, Hutchinson R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever M. Long-term

follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin. *Blood* 96(9):2981-2986, 2000.

109. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DA, Theil K, Mohamed A, Paietta E, Willman C, Head DR, Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: Southwest Oncology Group/Eastern Cooperative Oncology Group study. *Blood* 96(13):4075-4083, 2000.
110. Petersdorf SH, Kopecky KJ, Head DR, Boldt DH, Balcerzak SP, Wun T, Roy V, Veith RW, Appelbaum FR. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group study. *Leukemia* 15:208-216, 2001.
111. Garrido SM, Cooper JJ, Appelbaum FR, Willman CL, Kopecky KJ, Banker DE. Blasts from elderly acute myeloid leukemia patients are characterized by low levels for culture- and drug-induced apoptosis. *Leuk Res* 25(1):23-32, 2001.
112. Toyota M, Kopecky KJ, Toyota M-O, Jair K-W, Willman CL and Issa JPJ. Methylation profiling in acute myeloid leukemia. *Blood* 97(9):2823-2829, 2001.
113. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Radich JP, Willman CL. FLT3, Ras, and TP53 mutations in elderly patients with acute myeloid leukemia. *Blood* 97(11):3589-3595, 2001.
114. Sinclair WK, Agnew H, Beck HL, Christy RF, Clark SB, Harley NH, Kellerer AM, Kopecky KJ, Lowder WM, Weinberg AM, Young RW, Zaider M. Committee on dosimetry for the Radiation Effects Research Foundation. (Status of the Dosimetry for the Radiation Effects Research Foundation (DS86). National Academy Press, Washington DC, 2001.
115. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia. A Southwest Oncology Group Study. *Blood* 98(12):3212-3220, 2001.
116. Kopecky KJ, List AF, Appelbaum FR. Response: benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia. *Blood* 100(1):367, 2002.
117. List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, Dakhil SR, Appelbaum FR. Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. *Blood* 100(5):1910-1912, 2002.
118. Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW, Norwood TH, Chen I-M, Balcerzak SP, Johnson DB, Appelbaum FR. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. *Blood* 100(12):3869-3876, 2002.
119. Hsi ED, Kopecky KJ, Appelbaum FR, Boldt D, Frey T, Loftus M, Hussein MA. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia (CLL). *Br J Haematol* 120(6):1017-1025, 2003.
120. Shakhtarin VV, Tsyb AF, Stepanenko VF, Orlov MY, Kopecky KJ, Davis S. Iodine deficiency, radiation dose, and the risk of thyroid cancer among children and adolescents in the Bryansk region of Russia following the Chernobyl power station accident. *Int J Epidemiol* 32:584-591, 2003.

121. Cheson BD, Bennett JM, Kopecky KJ, Bloomfield CD, Büchner T, Willman C, Schiffer CA, Estey E, Döhner H, Tallman M, Lister TA, LoCocco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R. Recommendations of the International Working Group to standardize response criteria and treatment outcomes for therapeutic trials in acute myeloid leukemia. *J Clin Oncol* 21(24):4642-4649, 2003.
122. Stram DO, Kopecky KJ. Power and uncertainty analysis of epidemiologic studies of radiation-related disease risk in which dose estimates are based on a complex dosimetry system: some observations. *Radiat Res* 160(4):408-417, 2003.
123. Kopecky KJ, Davis S, Hamilton TE, Saporito MS, Onstad LE. Estimation of thyroid radiation doses for the Hanford Thyroid Disease Study: results and implications for statistical power of the epidemiological analyses. *Health Phys* 87(1):15-32, 2004.
124. Davis S, Stepanenko V, Rivkind N, Kopecky KJ, Voillequé P, Shakhtarin V, Parshkov E, Kulikov S, Lushnikov E, Abrosimov A, Troshin V, Romanova G, Doroschenko V, Proshin A, Tsyb A. Risk of thyroid cancer in the Bryansk Oblast of the Russian Federation after the Chernobyl Power Station accident. *Radiat Res* 162:241-248, 2004.
125. McCarthy PL, Jr, Paltiel O, Maslova E, Kulikov S, Hahn T, Kopecky KJ, Drozdova V, Shmatina N, Tichonova L, Van Hoff J, Gavrilova I, Weinstein H. Histopathologic verification of acute leukemia (AL) in a cohort of 463 post-Chernobyl patients from Belarus, Russia and Ukraine. *Leuk Res* 28(12):1273-1280, 2004.
126. Davis S, Kopecky KJ, Hamilton TE, Onstad L, Hanford Thyroid Disease Study Team. Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the Hanford Nuclear Site. *JAMA* 292(21):2600-2613, 2004.
127. Kopecky KJ, Onstad L, Hamilton TE, Davis S. Thyroid ultrasound abnormalities in persons exposed during childhood to ¹³¹I from the Hanford Nuclear Site. *Thyroid* 15(6):604-613, 2005.
128. Kopecky KJ, Green S. Noninferiority Trials. In *Handbook of Statistics in Clinical Oncology: Second edition* (J Crowley, DP Ankerst, eds). CRC Press, 2005.
129. Hamilton TE, Davis S, Onstad L, Kopecky KJ. Hyperparathyroidism in persons exposed to iodine-131 from the Hanford nuclear site. *J Clin Endocrinol Metab* 90(12):6545-6548, 2005.
130. Davis S, Day RW, Kopecky KJ, et al. Childhood leukaemia in Belarus, Russia, and Ukraine following the Chernobyl power station accident: results from an international collaborative population-based case-control study. *Int J Epidemiol* 35:386-396, 2006.
131. Cardis E, Howe G, Ron E, Bebeshko V, Bogdanova T, Bouville A, Carr Z, Chumak V, Davis S, Demidchik Y, Drozdovitch V, Gentner N, Gudzenko N, Hatch M, Ivanov V, Jacob P, Kapitonova E, Kenigsberg Y, Kesminiene A, Kopecky KJ, et al. Cancer consequences of the Chernobyl accident: 20 years on. *J Radiol Prot* 26:127-140, 2006.
132. Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. *Blood* 107(9):3724-3726, 2006.
133. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, Gundacker H, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. *Blood* 108(2):685-696, 2006.

134. Kopecky KJ, Stepanenko V, Rivkind N, Voillequé P, Onstad L, Shakhtarin V, Parshkov E, Kulikov S, Lushnikov E, Abrosimov A, Troshin V, Romanova G, Doroschenko V, Proshin A, Tsyb, A, Davis S. Childhood thyroid cancer, radiation dose from Chernobyl, and dose uncertainties in Bryansk Oblast, Russia: a population-based case-control study. *Radiat Res* 166:367-374, 2006.
135. Kimmel RR, Zhao LP, Nguyen D, Lee S, Aronszajn M, Cheng C, Troshin VP, Abrosimov A, Delrow J, Tuttle RM, Tsyb AF, Kopecky KJ, Davis S, Neiman PE. Microarray comparative genomic hybridization reveals genome-wide patterns of DNA gains and losses in post-Chernobyl thyroid cancer. *Radiat Res* 166(3):519-531, 2006.
136. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, Estey EH. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. *Br J Haematol* 135:165-173, 2006.
137. Weiss JR, Kopecky KJ, Godwin J, Anderson I, Willman CL, Moysich KB, Slovak ML, Hoque A, Ambrosone CB. Glutathione S-transferase (GSTM1, GSTT1, and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials. *Leukemia* 20:2169-2171, 2006.
138. Kuptsova N, Kopecky KJ, Godwin J, Anderson J, Hoque A, Willman CL, Slovak ML, Ambrosone CB. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. *Blood* 109(9):3936-3944, 2007.
139. Stram DO, Thomas DC, Kopecky KJ. Re: Hypothesis testing, statistical power, and confidence limits in the presence of epistemic uncertainty. *Health Physics* 93(4):326-327, 2007. PMID: 17846531
140. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogossova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery D, Wood N, Heimfeld S, Radich JP. Identification of genes with abnormal expression changes in acute myeloid leukemia. *Genes Chromosomes Cancer* 47(1):8-20, 2008. PMID: 17910043
141. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. *Blood* 111(5):2563-2572, 2008. PMID: 18156492, PMCID: [PMC2254550](#)
142. Davis S, Onstad L, Kopecky KJ, Wiggins C, Hamilton TE. Locating members of a cohort identified retrospectively from limited data in 50-year-old records: Successful approaches employed by the Hanford Thyroid Disease study. *Ann Epidemiol* 18(3):187-195, 2008. PMID: 18201901
143. Hamilton TE, Davis S, Onstad L, Kopecky KJ. Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism. *J Clin Endocrinol Metab* 93(4):1224-1230, 2008. PMID: 18230665, PMCID: [PMC2729186](#)
144. Erba HP, Kopecky KJ, Kirschbaum MH, Tallman MS, Larson RA, Willman CL, Slovak ML, Gundacker HM, Appelbaum FR. Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): North American Intergroup Study S0432. *Ann Hematol* 87(Suppl 1):S57-S59, 2008.
145. Tuttle RM, Lukes Y, Onstad L, Lushnikov E, Abrosimov A, Troshin V, Tsyb A, Davis S, Kopecky KJ, Francis G. ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults

exposed to Chernobyl fallout. *Thyroid* 18(8):839-846, 2008. PMID: 18690796 PMCID: [PMC2857448](#)

146. Schwartz JL, Kopecky KJ, Mathes RW, Leisenring WM, Friedman DL, Deeg HJ. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. *Radiat Res* 171(2):155-163, 2009. PMCID: [PMC2662700](#)
147. Becker PS, Kopecky KJ, Wilks AN, Chien S, Harlan JM, Willman CL, Petersdorf SH, Stirewalt DL, Papayannopoulou T, Appelbaum FR. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. *Blood* 113(4):866-874, 2009. PMCID: [PMC2630271](#)
148. Koreth J, Schlenk R, Kopecky K, Honda S, Sierra J, Djulbegovic B, Wadleigh M, DeAngelo D, Stone R, Sakamaki H, Appelbaum F, Döhner H, Antin J, Soiffer R, Cutler C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA* 301(22):2349-2361, 2009. PMID: 19509382
149. Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ, Appelbaum FR. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. *Br J Haematol* 117(1):48-58, 2009. PMID: 19821823 [NIHMS152440](#)
150. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Reaman GH, Baker LH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Molecular alterations of the *IDH1* gene in AML: a Children's Oncology Group and Southwest Oncology Group study. *Leukemia* 24(5):909-913, 2010. PMID: 20376086. PMCID: [PMC2945692](#)
151. McDougall JA, Sakata R, Sugiyama H, Grant E, Davis S, Nishi N, Soda M, Shimizu Y, Tatsukawa Y, Kasagi F, Suyama A, Ross P, Kopecky KJ, Li CI. Timing of menarche and first birth in relation to risk of breast cancer in A-bomb survivors. *Cancer Epidemiol Biomarkers Prev* 19(7):1746-1754, 2010. PMID: 20570914
152. Kuptsova-Clarkson N, Ambrosone CB, Weiss J, Baer MR, Sucheston LE, Zirpoli G, Kopecky KJ, Ford L, Blanco J, Wetzler M, Moysich KB. *XPD* DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia. *Int J Mol Epidemiol Genet* 1(4):278-294, 2010. PMID: None
153. De Roos AJ, Deeg HJ, Onstad L, Kopecky KJ, Aiello Bowles EJ, Yong M, Fryzek J, Davis S. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. *Am J Hematol* 85(10):765-770, 2010. PMID: 20815079
154. Li CI, Nishi N, McDougall JA, Semmens EO, Sugiyama H, Soda M, Sakata R, Hayashi M, Kasagi F, Suyama A, Mabuchi K, Davis S, Kodama K, Kopecky KJ. Relationship between radiation exposure and risk of second primary cancers among atomic bomb survivors. *Cancer Res* 70(18):7187-7198, 2010. PMID: 20843820. PMCID: [PMC2941904](#)

In Press:

Accepted:

Submitted:

In Preparation:

Nishi N, Li CI, Furukawa K, Sugiyama H, Sakata R, Grant EJ, Soda M, Shimizu Y, Kasagi F, Suyama A, Ozasa K, Mabuchi K, Davis S, Kopecky KJ, Kodama K. Cohort-based risk evaluation of second primary cancers among atomic bomb survivors.

Shakhtarin VV, Tsyb AF, Stepanenko VF, Gavrylin YuI, Bilyk EA, Davis S, Kopecky KJ. Radiogenic thyroid cancer in Bryansk Oblast after the Chernobyl accident: effect of medical examination, adequacy of models of radiation doses reconstruction.

Semmens EO, Grant E, ..., Kopecky KJ, et al. Potential influence of anthropometric factors on associations between radiation and colon cancer incidence in atomic bomb survivors in the Life Span Study cohort.

Submitted Abstracts:

Kesminiene A, Astakhova L, Davis S, Ivanov V, Kopecky KJ, et al. Risk of thyroid cancer following exposure to ¹³¹I early in life: a combined analysis of six studies. 12th International Congress of the International Radiation Protection Association, 2008.

Nishi N, Li CI, Furukawa K, Sugiyama H, Sakata R, Soda M, Shimizu Y, Kasagi F, Suyama A, Mabuchi K, Davis S, Kopecky KJ, Kodama K. Risk of second primary cancers among atomic bomb survivors. 18th World Congress of Epidemiology, 2008.

Semmens E, McDougall J, Nishi N, Davis S, Kopecky KJ, Li CI. Acute radiation exposure and risk of second primary cancers in atomic bomb survivors. International Society for Environmental Epidemiology, 2009.

Basu S, Chien S, Zhao A, Kopecky KJ, et al. Interaction of human acute myeloid leukemia cells with the bone marrow stromal microenvironment and correlation with clinical response. ASH 2010.

**ADDENDUM TO CURRICULUM VITAE:
Non-Publication Activities**

Kenneth J. Kopecky, Ph.D.

Radiation Epidemiology: Research in Progress

1. Case-control study of thyroid cancer following exposure to Chernobyl fallout in Bryansk Oblast, Russia.
2. Case-control study of breast cancer following exposure of women in Bryansk Oblast, Russia to Chernobyl fallout.
3. Methods for assessing joint effects of radiation and intermediate risk factors in nested case control studies.
4. Cancer mortality among military participants at U.S. nuclear weapons tests.

Southwest Oncology Group: Research in Progress

1. Intergroup phase IIb study of imatinib dose and dasatinib in chronic phase CML (S0325).
2. Phase II study of double induction chemotherapy for previously untreated adult ALL (S0333).
3. Phase II and III studies in acute promyelocytic leukemia (S0521 and S0535).
4. Phase II study of ara-C/clofarabine in relapsed/refractory ALL (S0530).
5. Phase II study of lenolidamide for -5/del(5q) AML in elderly patients (S0605).
6. Phase II study of azacytidine plus gemtuzumab ozogamicin in older patients with non-M3 AML (S0703).
7. Phase II study of hyper-CVAD, dasatinib and allogeneic stem cell transplantation in Ph+ or BCR/ABL+ ALL (S0805).
8. Clinicopathological significance of CaMKII γ activation in AML (S9333A).
9. Prognostic significance of AML-specific and age-associated genes in AML (S9031-S9126-S9333-S9500-A).
10. Topoisomerase II expression and AML (S9031-S9126-S9333-S9500-B).
11. Prognostic factors in CML progression and therapy resistance (S9032-S9300-A).
12. IDH1 mutation in AML.
13. Prognostic effect of BIK expression in AML.
14. Age-related genetic factors in AML.
15. Evaluation of phospho-flow cytometry in AML.
16. Proteome signatures and biomarkers in acute leukemia.

**ADDENDUM TO CURRICULUM VITAE:
Recent Published Abstracts**

Kenneth J. Kopecky, Ph.D.

1. Appelbaum FR, Kopecky KJ, Slovak ML, Gundacker, HM, et al. The clinical spectrum of adult acute myeloid leukemia (AML) associated with core binding factor (CBF) translocations. *J Clin Oncol* 23(16S):563s (#6513), 2005.
2. Becker PS, Papayannopoulou T, Kopecky KJ, Hanks AN, Harlan JM, Willman CL, Appelbaum FR. Very late antigen-4 (VLA-4) expression by AML blasts: correlation of VCAM-1 binding to overall survival. *Blood* 106 (11):#2365, 2005
3. Kopecky KJ, Williams LA. Modeling effects of radiation exposure on disease outcomes with radiation-influenced risk factors (RFs), using Adult Health Study (AHS) data. Joint Statistical Meetings, 2007.
4. Erba HP, Kopecky KJ, et al. Phase II studies of different schedules and doses of the farnesyl transferase inhibitor tipfarnib (R115777, Zarnestra, NSC-702818) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): a North American Intergroup Study. *Blood* 110(11):#440, 2007.
5. Wang CY, Kopecky KJ. Functional methods using biomarker data to account for dose uncertainty in estimating disease dose-response relationships. ASA Conference on Radiation and Health, 2008.
6. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. *Blood* 114(22):#790, 2009.
7. Kuptsova-Clarkson N, Ambrosone C, Weiss J, Baer MR, Sucheston L, Zirpoli G, Kopecky K, et al. *XPD* DNA nucleotide excision repair (NER) gene polymorphisms associated with DNA repair deficiency may predict better treatment outcomes in secondary acute myeloid leukemia (AML). *Blood* 114(22):#168, 2009.
8. Becker P, Chien S, Roshal M, Wood B, Estey E, Papayannopolou T, Zhao A, Basu S, McGrath M, Kopecky K, Appelbaum F. Adhesion receptor expression by acute myeloid leukemia (AML) blasts, AML stem cells, and comparison of bone marrow versus circulating blasts. *Blood* 114(22) :#2658, 2009.
9. Pogosova-Agadjanyan EL, Kopecky KJ, et al. Over-expression of Novel *IRF8* Splice Variants is Associated with a Significant Decrease in Relapse-Free Survival in adult AML Patients. Accepted, ASH 2010.
10. Ho, PA, Alonzo TA, Kopecky KJ, et al. Prognostic implications of the *IDH1* synonymous SNP rs11554137 in pediatric and adult AML: a Children's Oncology Group and Southwest Oncology Group Study. Accepted, ASH 2010.